CLINICAL SCIENCE

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles-Schoeman 1, Maya H Buch 2,3, Maxime Dougados 4,5, Deepak L Bhatt 6, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A Connell, Zoltan Szekanecz 15

ABSTRACT

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance.

Methods Patients with RA aged ≥50 years with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. Hazard ratios (HRs) were evaluated for the overall population and by history of ASCVD (exploratory analysis).

Results Risk of MACE, myocardial infarction and sudden cardiac death were increased with tofacitinib versus TNFi in ORAL Surveillance. In patients with history of ASCVD (14.7%; 640/4362), MACE incidence was higher with tofacitinib 5 mg two times per day (8.3%; 17/204) and 10 mg two times per day (7.7%; 17/222) versus TNFi (4.2%; 9/214). HR (combined tofacitinib doses vs TNFi) was 1.98 (95% confidence interval (CI) 0.95 to 4.14; interaction p values: 0.196 (for HR)/0.059 (for incidence rate difference)). In patients without history of ASCVD, MACE HRs for tofacitinib 5 mg two times per day (2.4%; 30/1251) and 10 mg two times per day (2.8%; 34/1234) versus TNFi (2.3%; 28/1237) were, respectively, 1.03 (0.62 to 1.73) and 1.25 (0.76 to 2.07).

Conclusions This post hoc analysis observed higher MACE risk with tofacitinib versus TNFi in patients with RA and history of ASCVD. Among patients without history of ASCVD, all with prevalent CV risk factors, MACE risk did not appear different with tofacitinib 5 mg two times per day versus TNFi. Due to the exploratory nature of this analysis and low statistical power, we cannot exclude differential MACE risk for tofacitinib 5 mg two times per day versus TNFi among patients without history of ASCVD, but any absolute risk excess is likely low.

Trial registration number NCT02092467.

INTRODUCTION

Compared with the general population, individuals with rheumatoid arthritis (RA) have a greater risk of cardiovascular (CV) disease.1 2 This is attributed to RA-associated systemic inflammation and traditional CV risk factors,2–7 and both require effective control to mitigate the risk. The European Alliance of Associations for Rheumatology (EULAR) recommends regular CV risk assessments in patients with RA using validated risk prediction models.2

ORAL Surveillance was a post-authorisation safety study conducted, in part, due to observations of increased serum lipid levels with the Janus kinase inhibitor, tofacitinib.8–10 The study was the first to evaluate the relative risk of adjudicated major adverse cardiovascular events (MACE) and malignancies with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with RA aged ≥50 years with ≥1 additional CV risk factor. For combined tofacitinib doses (5 mg and 10 mg two times per day) versus TNFi, non-inferiority was not shown for adjudicated MACE (incidence rate (IR) of 0.98 per 100 patient-years, 95% CI 0.79 to 1.19,
WHAT THIS STUDY Adds

⇒ This post hoc analysis of ORAL Surveillance shows an increased risk of MACE with tofacitinib 5 mg and 10 mg two times per day versus TNFi that was primarily observed in patients with a history of atherosclerotic cardiovascular disease (ASCVD; ie, history of coronary artery disease, cerebrovascular disease or peripheral artery disease) at baseline.

⇒ Risk of MACE did not appear different with tofacitinib 5 mg two times per day versus TNFi in patients without a history of ASCVD; but, given the exploratory nature of the analysis and the low event rate, we cannot rule out an increased risk of MACE in patients with several CV risk factors.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This exploratory analysis of MACE in ORAL Surveillance underscores the value of including patients with a history of ASCVD for appropriate risk enhancement when investigating CV safety of RA treatments.

⇒ Our findings emphasise the importance of rheumatologists assessing overall CV risk, including medical history of ASCVD, when considering tofacitinib as a treatment for patients with RA.

METHODS

Study design and patients

ORAL Surveillance (NCT02092467) was a phase IIIb/IV randomised, open-label, non-inferiority, safety endpoint study conducted from March 2014 to July 2020 in patients with active moderate-to-severe RA despite methotrexate treatment who were aged ≥50 years with ≥1 additional CV risk factor (current smoking, hypertension, high-density lipoprotein cholesterol (HDL-c) <40 mg/dL, diabetes mellitus, family history of premature coronary heart disease (CHD), RA-associated extra-articular disease and/or history of CAD). Patients were randomised 1:1:1 to receive oral tofacitinib 5 mg or 10 mg two times per day, or subcutaneous TNFi (adalimumab 40 mg every 2 weeks (North America) or etanercept 50 mg once weekly (rest of the world)). All patients continued their prestudy stable dose of methotrexate unless modification was clinically indicated. In February 2019, the tofacitinib 10 mg two-times-per-day dose was reduced to 5 mg two times per day after the Data Safety Monitoring Board noted an increased frequency of pulmonary embolism in patients receiving tofacitinib 10 mg two times per day versus TNFi and an increase in overall mortality with tofacitinib 10 mg versus 5 mg two times per day and TNFi.

Evaluation of history of ASCVD and baseline CV risk

A history of ASCVD was defined as the composite of history of CAD, CeVD and PAD. A history of CAD was an eligibility criterion in ORAL Surveillance (reported as ≥one of history of myocardial infarction (MI), unstable angina, stable angina pectoris, coronary artery procedures or other CHD). A history of CeVD (including ischaemic stroke and transient ischaemic attack) and PAD was identified in patients’ general medical history through Medical Dictionary for Regulatory Activities’ preferred terms (online supplemental table 1).

In patients without a history of ASCVD, 10-year risk of events associated with ASCVD (ie, MACE) was calculated by ASCVD-Pooled Cohort Equations (ASCVD-PCE). Scores were calculated based on patients’ baseline age, sex, race (white/black/other), smoking status (yes/no), systolic blood pressure, anti-hypertensive treatment (yes/no), total cholesterol, HDL-c and diabetes (yes/no). In line with EULAR recommendations, a 1.5 multiplier was applied to all ASCVD-PCE scores. Based on the resulting scores, and as suggested by the American College of Cardiology/American Heart Association, patients without a history of ASCVD were assigned to the following 10-year risk categories: high (≥20%), intermediate (≥7.5–<20%), borderline (≥5–<7.5%) and low (<5%).

Outcomes

MACE and its components were based on adjudicated events assessed by an external, independent adjudication committee.

Table 1: ASCVD is defined based on events, diagnoses and procedures associated with atherosclerosis in arteries of the heart, head and neck and the periphery.

<table>
<thead>
<tr>
<th>Group</th>
<th>Events</th>
<th>Diagnoses</th>
<th>Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD</td>
<td>MI; unstable angina</td>
<td>CHD; stable angina pectoris</td>
<td>Coronary artery revascularisation; coronary artery bypass grafting</td>
</tr>
<tr>
<td>CeVD</td>
<td>Ischaemic stroke; transient ischaemic attack</td>
<td>Carotid artery stenosis; carotid atherosclerosis</td>
<td>Carotid endarterectomy</td>
</tr>
<tr>
<td>PAD</td>
<td>Peripheral artery thrombosis</td>
<td>Aortic atherosclerosis; intermittent claudication</td>
<td>Peripheral artery angioplasty</td>
</tr>
</tbody>
</table>

Events, diagnoses and procedures mentioned are examples, the list is not exhaustive. A complete list of terms used to define history of ASCVD in the present study is shown in online supplemental table 1.

ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; CeVD, cerebrovascular disease; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease.
<table>
<thead>
<tr>
<th>Demographic and baseline disease characteristics in the ORAL Surveillance overall population and in patients with and without a history of ASCVD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall</strong></td>
</tr>
<tr>
<td><strong>Tofacitinib 5 mg two times per day (N=1455)</strong></td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>≥65 years, n (%)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
</tr>
<tr>
<td>History of ASCVD, n (%)</td>
</tr>
<tr>
<td>History of CAD</td>
</tr>
<tr>
<td>History of CeVD</td>
</tr>
<tr>
<td>History of PAD</td>
</tr>
<tr>
<td>10-year risk of MACE, n (%)*</td>
</tr>
<tr>
<td>High (≥20%)</td>
</tr>
<tr>
<td>Intermediate (≥7.5–&lt;20%)</td>
</tr>
<tr>
<td>Borderline (≥5–&lt;7.5%)</td>
</tr>
<tr>
<td>Low (&lt;5%)</td>
</tr>
<tr>
<td>Smoking status, n (%)†</td>
</tr>
<tr>
<td>Current smoker</td>
</tr>
<tr>
<td>Past smoker</td>
</tr>
<tr>
<td>Never smoked</td>
</tr>
<tr>
<td>History of diabetes mellitus, n (%)</td>
</tr>
<tr>
<td>History of hypertension, n (%)</td>
</tr>
<tr>
<td>History of hyperlipidaemia, n (%)</td>
</tr>
<tr>
<td>Family history of CHD, n (%)</td>
</tr>
<tr>
<td>First-degree male relative &lt;55 years</td>
</tr>
<tr>
<td>First-degree female relative &lt;55 years</td>
</tr>
<tr>
<td>Baseline corticosteroids, n (%)†</td>
</tr>
<tr>
<td>Baseline antiplatelets including aspirin, n (%)†</td>
</tr>
<tr>
<td>Baseline statins, n (%)†</td>
</tr>
<tr>
<td>Prior use of TNFi, n (%)</td>
</tr>
</tbody>
</table>

* A 10-year risk of MACE was calculated with the ASCVD-PCE calculator and a 1.5 multiplier was applied for RA, as recommended by EULAR.15

† Based on day 1 of treatment with tofacitinib or TNFi in ORAL Surveillance.

ASCVD, atherosclerotic cardiovascular disease; ASCVD-PCE, atherosclerotic cardiovascular disease-Pooled Cohort Equations; CAD, coronary artery disease; CeVD, cerebrovascular disease; CHD, coronary heart disease; EULAR, European Alliance of Associations for Rheumatology; MACE, major adverse cardiovascular events; n, number of patients with characteristic; N, number of patients in the safety population; PAD, peripheral artery disease; RA, rheumatoid arthritis; SD, standard deviation; TNFi, tumour necrosis factor inhibitor.
Rheumatoid arthritis

MACE was defined as the composite of CV death (ie, death due to MI, stroke, sudden cardiac death, heart failure, CV procedures, CV haemorrhage and other CV causes, but not death due to pulmonary embolism), non-fatal MI and non-fatal stroke (including reversible focal neurological defects with imaging evidence of a new cerebral lesion consistent with ischaemia or haemorrhage).

Statistical analyses

Outcomes were analysed using the safety analysis set, which included all randomised patients receiving ≥1 dose of study drug. For patients randomised to tofacitinib 10 mg two times per day who had their dose reduced to 5 mg two times per day in February 2019, the data collected after the dose switch were counted in the tofacitinib 10 mg two times per day group. HRs and 95% CIs were NI when the total number of patients with events was ≤2 for the corresponding pair of treatments in the comparison or when one of the treatments in the comparison had 0 events. IRs express number of patients with first events per 100 PY.†Results reported in Ytterberg et al8 and included for reference. HR 95% CI excludes 1. BID, two times per day; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; IR, incidence rate; MACE, major adverse cardiovascular events; MI, myocardial infarction; n, number of patients with events; N, number of evaluable patients; NI, non-informative; PY, patient-years; TNFi, tumour necrosis factor inhibitor.

Figure 1 Adjudicated MACE outcomes with tofacitinib versus TNFi in ORAL Surveillance. HRs are shown on a logarithmic scale. Arrows indicate that the CI extends beyond the graph axis. For patients randomised to the tofacitinib 10 mg two-times-per-day group who had their dose of tofacitinib reduced to 5 mg two times per day, the data collected after patients were switched to tofacitinib 5 mg two times per day were counted in the tofacitinib 10 mg two-times-per-day group. HRs (95% CIs) are based on two simple Cox proportional hazard models (one for comparing combined tofacitinib doses vs TNFi, and the other for comparing tofacitinib 5 mg and 10 mg two times per day vs TNFi), with treatment as the only covariate. HRs and 95% CIs were NI when the total number of patients with events was ≤2 for the corresponding pair of treatments in the comparison or when one of the treatments in the comparison had 0 events. IRs express number of patients with first events per 100 PY. Results reported in Ytterberg et al8 and included for reference. HR 95% CI excludes 1. BID, two times per day; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; IR, incidence rate; MACE, major adverse cardiovascular events; MI, myocardial infarction; n, number of patients with events; N, number of evaluable patients; NI, non-informative; PY, patient-years; TNFi, tumour necrosis factor inhibitor.
Rheumatoid arthritis

Subgroup analyses were conducted to assess for an association between history of ASCVD or baseline risk of MACE (ie, categories of CV risk in patients without history of ASCVD) with risk (HRs and IRs) of MACE, MI and stroke with tofacitinib versus TNFi. Across these exploratory analyses, no multiplicity adjustments were applied. Statistical analyses of treatment by history of ASCVD interactions are described in the online supplemental material.

The number needed to harm (NNH) was calculated as the reciprocal of the difference in IRs between tofacitinib and TNFi. Positive NNH was defined as patient-years of tofacitinib exposure needed for one more patient to report an additional event versus TNFi. Negative NNH was defined as the reverse. When the 95% CI of the IR difference includes 0, the 95% CI of the NNH has 2 disjoint (positive and negative) intervals, implying harm in either tofacitinib versus TNFi (positive) or TNFi versus tofacitinib (negative). NNH for patients exposed for 5 years was calculated by dividing the number of patient-years needed to harm by 5.

**Patient and public involvement**

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

**RESULTS**

**Patients**

In total, 4362 patients were randomised and treated (tofacitinib 5 mg two times per day, n=1453; tofacitinib 10 mg two times per day, n=1456; TNFi, n=1453). Median follow-up was 4.0 years; 3111/4362 (71.3%) patients completed the trial and 2745/4362 (62.9%) completed trial treatment. Full patient demographics and baseline disease characteristics are described elsewhere. Table 2 summarises...
Rheumatoid arthritis

CV risk factors and the CV risk profile (online supplemental figure 1) of the study population versus patients with and without a history of ASCVD. These were well-balanced across treatment groups in ORAL Surveillance; 14.7% (640/4362) of patients had a history of ASCVD. Patients with a history of ASCVD were more likely to be ≥65 years, male, past smokers and have a history of diabetes mellitus, hypertension or hyperlipidaemia, compared with those with no history of ASCVD (table 2).

Risk of adjudicated MACE outcomes with tofacitinib versus TNFi in ORAL Surveillance

Risk of MACE, MI and sudden cardiac death were increased with both tofacitinib doses versus TNFi as reflected by HRs >1.0 and higher IRs (figure 1 and online supplemental figure 2). Risk of non-fatal MI with tofacitinib 5 mg two times per day versus TNFi was noticeably increased (HR=2.32; 95% CI 1.59 to 3.40; figure 1). Stroke HRs and IRs across treatment groups are shown in figure 1 and online supplemental figure 2.

Across treatment groups, the most frequent cause of CV death was sudden cardiac death (figure 1). One patient had fatal heart failure (tofacitinib 10 mg two times per day), and one died of other CV causes (TNFi).

HRs for MACE with tofacitinib versus TNFi in a total time analysis, including all events up to last contact date regardless of when study drug was discontinued, were consistent with the primary analysis (online supplemental figure 3). MACE IRs by 6-month intervals are shown in online supplemental figure 4.

Risk of MACE with tofacitinib versus TNFi according to a history of ASCVD

Among patients with a history of ASCVD, MACE was reported in 17/204 (8.3%), 17/222 (7.7%) and 9/214 (4.2%) of patients in the tofacitinib 5 mg two-times-per-day, tofacitinib 10 mg two-times-per-day and TNFi treatment groups, respectively. MACE HRs (95% CIs) were 1.96 (0.87 to 4.40) for tofacitinib 5 mg two times per day versus TNFi, 2.01 (0.90 to 4.40) for tofacitinib 10 mg two times per day versus TNFi and 1.98 (0.95 to 4.14) for combined tofacitinib doses versus TNFi (figure 2A and online supplemental figure 5). Based on the IR differences, this corresponds to NNH of 16 (95% CI −∞ to −91 and 7 to ∞) and 15 (95% CI −∞ to −117 and 7 to ∞) patients who would need to be treated with tofacitinib 5 mg and 10 mg two times per day, respectively, versus TNFi, over 5 years to have 1 additional MACE (figure 2A; online supplemental table 2).

In patients without a history of ASCVD but with CV risk factors, MACE was reported in 30/1251 (2.4%), 34/1234 (2.8%) and 28/1237 (2.3%), in the tofacitinib 5 mg two-times-per-day, tofacitinib 10 mg two-times-per-day and TNFi treatment groups, respectively (figure 2A). HRs (95% CI) for MACE were 1.03 (0.62 to 1.73) for tofacitinib 5 mg two times per day versus TNFi,
1.25 (0.76 to 2.07) for tofacitinib 10 mg two times per day versus TNFi and 1.14 (0.73 to 1.78) for combined tofacitinib doses versus TNFi (figure 2A and online supplemental figure 5). Based on the IR differences, this corresponds to NNH of 869 (95% CI −∞ to −64 and 55 to ∞) and 124 (95% CI −∞ to −100 and 38 to ∞) patients who would need to be treated with tofacitinib 5 mg and 10 mg two times per day, respectively, versus TNFi, over 5 years to have 1 additional MACE (figure 2A; online supplemental table 2). P values for the treatment by history of ASCVD interaction (combined tofacitinib doses vs TNFi) for MACE were 0.196 for the HRs and 0.059 for the IR difference (figure 2B).

Kaplan-Meier curves for MACE (figure 2C) indicated separation between the tofacitinib and TNFi groups by month 3 in patients with history of ASCVD, and no separation between treatment groups in patients without history of ASCVD.

Association between baseline CV risk scores and risk of MACE, MI and stroke with tofacitinib versus TNFi in patients without a history of ASCVD

Patients without a history of ASCVD were grouped by their 10-year risk of MACE. 2 MACE IRs, regardless of treatment group, were highest in patients at high risk (ie, ≥20% 10-year risk of MACE) (figure 4 and online supplemental figure 6). There was no difference in risk of MACE with tofacitinib 5 mg or 10 mg two times per day versus TNFi in patients at high or intermediate risk. While HRs for tofacitinib versus TNFi were >1.0 in patients with low or borderline risk, the number of events was low.

MI IRs were highest in patients with a high CV risk score (figure 5 and online supplemental figure 7). There was an increased risk of MI with tofacitinib 5 mg two times per day versus TNFi in patients with high 10-year risk of MACE. There were fewer MI reports in the other risk categories.
The association between baseline CV risk and stroke IRRs was less apparent than observed for MACE and MI (figure 6 and online supplemental file 8). Overall, event numbers in each risk category were low.

DISCUSSION

Primary analyses of ORAL Surveillance, which included patients aged ≥50 years with ≥1 additional CV risk factor and was the first study to evaluate tofacitinib safety in a CV risk-enriched RA population, found an increased risk of MACE with tofacitinib versus TNFi. In this post hoc analysis, increased risk of MACE was primarily identified in patients with a history of ASCVD (ie, pre-existing CAD, CeVD or PAD). In patients without a history of ASCVD but with CV risk factors, there did not appear to be a detectable difference in risk of MACE with tofacitinib 5 mg two times per day versus the combined tofacitinib doses versus TNFi.

ORAL Surveillance was powered to assess non-inferiority for risk of MACE with combined tofacitinib doses versus TNFi and not powered to compare individual MACE components across treatment groups. The exploratory analyses on CV outcomes and subgroup analyses we provide, therefore, need to be interpreted cautiously and as hypothesis-generating. Notwithstanding, our analysis of the overall study population supplements the primary analysis of the study and shows increased risk of MI and sudden cardiac death with tofacitinib versus TNFi in this CV risk-enriched population.

Almost 15% of the patients in ORAL Surveillance had a history of ASCVD. In this subgroup, we found increased risk of MACE, MI and stroke with tofacitinib versus TNFi. In the remaining 85% of patients without a history of ASCVD, who nevertheless had CV risk factors, we did not find increased relative risk of MACE with tofacitinib versus TNFi. This observation is supported by our assessment of relative risk across categories of predicted MACE risk; there was no clear difference in risk of MACE in patients without a history of ASCVD who had high (≥20%) or intermediate (≥7.5–<20%) predicted 10-year risk at baseline. Approximately one-third of the ORAL Surveillance population had low or borderline absolute risk of MACE, and the low number of MACE in this group makes assessment of relative risk less certain.

A large observational study that used USA claims data to assess risk of CV outcomes (composite of hospitalisation for MI or stroke) with tofacitinib versus TNFi in patients with RA (Safety of ToFacitinib in Routine care patients with Rheumatoid Arthritis; STAR-RA) was recently published. Evidence for an increased risk of CV outcomes with tofacitinib was not identified in this real-world evidence cohort. However, STAR-RA included a cohort that mirrored ORAL Surveillance inclusion
and exclusion criteria (randomised controlled trial (RCT)-duplicate cohort). The primary outcome of the RCT-duplicate cohort aligned with the increased risk of MACE with tofacitinib versus TNFi observed in ORAL Surveillance (ie, approximately 25% relative risk increase with tofacitinib 5 mg two times per day vs TNFi).8 19 STAR-RA also prespecified subgroup analyses of patients with or without previous CV disease. These results were also similar to ORAL Surveillance; risk of CV outcomes appeared to be increased with tofacitinib versus TNFi in patients with, but not in those without, pre-existing CV disease.19

Our analysis of MACE in ORAL Surveillance underscores the importance of investigating the long-term safety of RA treatments in appropriately designed, prospective, randomised and comparative trials of sufficient size and duration to adequately evaluate safety events of interest, including CV adverse events. Consequently, for ORAL Surveillance to be declared complete, ≥1500 patients had to be followed for 3 years and the study was conducted in a CV risk-enriched population to ensure accumulation of a sufficient number of CV events. To the best of our knowledge, the only similar studies in RA are the ENTRACTE and PRECISION trials that assessed CV safety of tocilizumab versus etanercept and celecoxib versus naproxen versus ibuprofen, respectively.27 28 In ENTRACTE and PRECISION, 11% (347/3080) and 24% (584/2436) of patients with RA had previous CV disease diagnoses, events and procedures consistent with ASCVD.11 21 In contrast, the wider tofacitinib RA clinical trial programme included 1.3% (100/7964) of patients with a history of MI and 0.4% (30/7964) with a history of CHD, and 39% (3126/7964) of tofacitinib-treated patients met the CV risk-enrichment criteria of ORAL Surveillance.22 Similarly, a recent report on the baricitinib RA clinical trial programme found that 35% (1325/3770) of patients met ORAL Surveillance inclusion criteria, and 2.3% had a history of ASCVD.23 The non-CV risk-enriched wider tofacitinib clinical trial programme did not identify the increased risk of MACE with tofacitinib versus TNFi that was observed in ORAL Surveillance. Based on our data, future trials with objectives overlapping with ORAL Surveillance should include sufficient patients with high absolute CV risk and history of ASCVD, and even prespecify the analysis we present herein.

Overall, limitations of ORAL Surveillance have been published previously.8 The exploratory nature and the lack of statistical evidence (ie, nominally significant p values) of a treatment by history of ASCVD interaction limits our conclusions on this subgroup analysis. This analysis points to a need for more data on risk of MACE with tofacitinib versus other advanced RA treatments in patients with increased CV risk but no history of ASCVD. The subgroup distribution was also uneven (14.7% with vs 85.3% without history of ASCVD). In the history of ASCVD group, across treatment arms, there were relatively few patients (N=204–222) and patients with MACE events (n=9–17). Accordingly, IRs and HRs should be regarded as statistically uncertain, as reflected in the wider 95% CIs, and be interpreted with caution. In addition, substantial literature supports the atheroprotective effects of TNFi, effects that

| Stroke | Overall population | Tofacitinib 5 mg BID | 18/1455 (1.2%) | 1.03 (0.53, 2.00) | 0.35 (0.21, 0.59) |
|        |                   | Tofacitinib 10 mg BID | 18/1456 (1.2%) | 1.10 (0.57, 2.13) | 0.37 (0.22, 0.58) |
|        |                   | Combined tofacitinib doses | 56/2911 (1.2%) | 1.06 (0.60, 1.98) | 0.36 (0.25, 0.49) |
|        |                   | TNFi                  | 17/1431 (1.2%) | 1.04 (0.57, 1.75) | 0.34 (0.20, 0.54) |
| HxASCVD | Tofacitinib 5 mg BID | 8/204 (3.9%) | 2.80 (0.74, 10.56) | 1.17 (0.51, 2.33) |
|        | Tofacitinib 10 mg BID | 6/222 (2.7%) | 2.10 (0.53, 8.41) | 0.90 (0.33, 1.96) |
|        | Combined tofacitinib doses | 14/426 (3.3%) | 2.45 (0.70, 8.54) | 1.04 (0.57, 1.75) |
|        | TNFi                  | 3/214 (1.4%) | 0.42 (0.09, 1.24) |
| High  >20% | Tofacitinib 5 mg BID | 3/258 (1.2%) | 0.52 (0.13, 2.09) | 0.35 (0.07, 1.01) |
|        | Tofacitinib 10 mg BID | 4/289 (1.4%) | 0.68 (0.19, 2.43) | 0.45 (0.12, 1.15) |
|        | Combined tofacitinib doses | 7/547 (1.3%) | 0.61 (0.20, 1.80) | 0.40 (0.16, 0.82) |
|        | TNFi                  | 6/278 (2.2%) | 0.66 (0.24, 1.44) |
| Intermediate >7.5—<20% | Tofacitinib 5 mg BID | 5/472 (1.1%) | 0.70 (0.22, 2.18) | 0.29 (0.09, 0.67) |
|        | Tofacitinib 10 mg BID | 4/490 (0.8%) | 0.56 (0.16, 1.92) | 0.23 (0.06, 0.59) |
|        | Combined tofacitinib doses | 9/962 (0.9%) | 0.63 (0.23, 1.69) | 0.26 (0.12, 0.49) |
|        | TNFi                  | 7/483 (1.4%) | 0.41 (0.17, 0.85) |
| Low − Borderline <7.5% | Tofacitinib 5 mg BID | 2/504 (0.4%) | 1.85 (0.17, 20.37) | 0.11 (0.01, 0.39) |
|        | Tofacitinib 10 mg BID | 3/437 (0.7%) | 3.37 (0.34, 31.40) | 0.19 (0.04, 0.56) |
|        | Combined tofacitinib doses | 5/941 (0.5%) | 2.50 (0.29, 21.38) | 0.15 (0.05, 0.34) |
|        | TNFi                  | 1/461 (0.2%) | 0.06 (0.00, 0.33) |

Figure 6  Risk of stroke with tofacitinib versus TNFi in patients without a history of ASCVD, according to CV risk categories. HRs are shown on a logarithmic scale. Arrows indicate that the CI extends beyond the graph axis. Patients without history of ASCVD were categorised according to their 10-year risk of MACE, per the ASCVD-PCE risk calculator. In line with EULAR recommendations, a 1.5 multiplier was applied to all ASCVD-PCE scores.8 Because of missing ASCVD-PCE score, one stroke in the tofacitinib 10 mg two-times-per-day group could not be associated with baseline CV risk. For patients randomised to the tofacitinib 10 mg two-times-per-day group who had their dose of tofacitinib reduced to 5 mg two times per day, the data collected after patients were switched to tofacitinib 5 mg two times per day were counted in the tofacitinib 10 mg two-times-per-day group. HRs (95% CIs) are based on two simple Cox proportional hazard models (one for comparing combined tofacitinib doses versus TNFi, and the other for comparing tofacitinib 5 mg and 10 mg two times per day vs TNFi), with treatment as the only covariate. IRs express the number of patients with first events per 100 PY. ASCVD-PCE, atherosclerotic cardiovascular disease-Pooled Cohort Equations; BID, two times per day; CV, cardiovascular; EULAR, European Alliance of Associations for Rheumatology; HxASCVD, history of atherosclerotic cardiovascular disease; IR, incidence rate; MACE, major adverse cardiovascular events; n, number of patients with events; N, number of evaluable patients; PY, patient-years; TNFi, tumour necrosis factor inhibitor.
likely extend to other immunomodulators via their ability to modulate syncytial and systemic inflammation. These treatment-associated effects cannot be assessed in ORAL Surveillance given the lack of an untreated control group, but the results we present should be interpreted in this context.

CONCLUSION

Our post hoc analysis of ORAL Surveillance showed that increased risk of MACE with tofacitinib 5 mg and 10 mg two times per day versus TNFi was found in patients with a history of ASCVD. Among patients without a history of ASCVD, who all had prevalent CV risk factors, risk of MACE did not appear to be different comparing tofacitinib 5 mg two times per day and TNFi. Due to the exploratory nature of this analysis and low statistical power, we cannot exclude any differential MACE risk for tofacitinib 5 mg two times per day versus TNFi among patients without HxASCVD, but any absolute risk excess is likely low.

Author affiliations
1Division of Rheumatology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA
2Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
3NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
4Université de Paris; Department of Rheumatology, Hôpital Cochin; Assistance Publique-Hôpitaux de Paris, Paris, France
5INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
6Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
7Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
8Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
9Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
10Pfizer Ltd, Tadworth, UK
11Pfizer Inc, New York, New York, USA
12Pfizer SLU, Madrid, Spain
13Pfizer Inc, Oslo, Norway
14Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Acknowledgements Select data in this manuscript were previously presented at ACR Convergence 2021. The authors would like to thank the patients, investigators, and study teams involved in the study. The authors would like to thank Hyejin Jo and Annette Szumski from Synco Health for their contribution to the statistical analyses. This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Kirsten Woolcott, MSc, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–4).

Contributors DLB, SRY, JJW, CW, KK, KY, AG and GC conceived or designed the study and data analyses. KK acquired the data. CC-S, DLB, JTG, SRY, JJW, CW, KK and KY analysed the data. All authors had access to the data, were involved in interpretation of data and reviewed and approved the manuscript’s content before submission. CC-S accepts final responsibility for this work and controlled the decision to publish.

Funding This study was sponsored by Pfizer Inc.

Competing interests CCS has acted as a consultant for AbbVie, Gilead Sciences, Pfizer Inc and Regeneron-Sanofi, and has received grant/research support from AbbVie, Bristol-Myers Squibb and Pfizer Inc. MHB has acted as a consultant for AbbVie, Eli Lilly, Gilead Sciences, MSD, Pfizer Inc and Roche, has received grant/research support from Pfizer Inc, Roche and UCB, and is a member of the speakers’ bureau for AbbVie (paid to host institution). MHB is supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre and is in receipt of an NIHR Senior Investigator award. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. MD has acted as a consultant for AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, and has received grant/research support from AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, and is a member of the speakers’ bureau for AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, a consultant for AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, has received grant/research support from Pfizer Inc and UCB, and is a member of the speakers’ bureau for AbbVie, Eli Lilly, MSD, Novartis, Pfizer Inc, Roche, Sanofi and UCB.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.
Participants gave informed consent to participate in the study before taking part.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  Data are available upon reasonable request. Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/scientific-trials/trial-data-and-results for more information.

Supplemental material  This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Christina Charles-Schoeman http://orcid.org/0000-0002-1768-7019
Maja H Buch http://orcid.org/0000-0002-8962-5642
Maxime Douagos http://orcid.org/0000-0003-3009-6229
Deeptak L Bhatt http://orcid.org/0000-0002-1278-6245
Zoltan Szekanecz http://orcid.org/0000-0002-1794-6844

REFERENCES